PARKINSON’S DISEASE (PD)

6.1 millions > 12 millions

Total Costs
13.9 B€/year

2016

Total Costs
2.34 B€/year

>1.400.000 patients

2050

400.000 patients
PD: CURRENT CLINICAL PRACTICE

- 100+ visits/month
- On average 3 visits/year
- Visual assessment of motor performance
- Latent symptoms during the visits remain undetected
- Therapy adjustment by phone or after months
- Self-reported symptoms and response to therapy changes
THE UNMET NEEDS

Co-Creation Workshops
Interview
Prioritization Analysis

Neurologists, Patients, Caregivers
and Healthcare Professionals
(50+ people)

Short time visits for patients’ complete motor evaluation
Subjectivity and variability in motor assessment
Unavailable PD patients remote monitoring
THE SOLUTION · WEARNCARE ·

A decision support tool for diagnosis, management and follow-up in Parkinson’s disease

One solution, multiple advantages

Digitalized and objective data
Objective remote monitoring
Better use of the resources
THE SYSTEM

IoT-enabled wearables for data acquisition and processing

Proprietary AI-based algorithms for feature extraction and data analytics

Interoperable Cloud platform for data storage, visual dashboard

At hospital for diagnosis support and follow-up visits

Connected home for therapy adjustment

WEARVCARE

COAIMED
COLLABORATIONS

Sheffield Hallam University, Sheffield, UK
Institute Claude Pompidou, Nice, France
Fundació Institut Guttmann, Badalona, Spain
Eurecat Centre Tecnològic de Catalunya, Barcelona, Spain
Biomedicina Sperimentale, Università di Palermo, Italy
IRCCS Istituto Auxologico Italiano, Milano, Italy
IRCCS Istituto Scienze Neurologiche, Bologna, Italy
Ospedale Apuane, Massa, Italy
AOU Careggi, Firenze, Italy
Ospedale Santa Maria Nuova, Firenze, Italy
IRCCS Fondazione Don Gnocchi, Firenze, Italy
CLINICAL EVIDENCE

400+ PEOPLE ALREADY TESTED IN HOSPITALS

EXCELLENT PRECISION & MODULARITY (Err<5%, TRL 7)

- Up to 100% accuracy in characterizing PD motor symptoms (healthy subjects vs. PD patients)
- Accurate monitoring of the motor subtle changes related to change in therapy
- >80% accuracy on PD progression (mild, moderate, advanced)

CLINICAL ASSESSMENT

THERAPY ADJUSTMENT

FOLLOW UP

CLINICAL EVIDENCE
# Competitors Analysis

<table>
<thead>
<tr>
<th>Feature</th>
<th>WEARNCARE</th>
<th>G WALK</th>
<th>Motognosis AMSA</th>
<th>Kinesia One</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor Symptoms</td>
<td>Bradykinesia Tremor</td>
<td>Bradykinesia</td>
<td>Bradykinesia</td>
<td>Bradykinesia Dyskinesia Tremor</td>
</tr>
<tr>
<td>Portable</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Sensors and placement</td>
<td>#4 fingers; #2 wrists; #2 feet</td>
<td>#1 trunk L2-S1</td>
<td>#1 index finger or foot</td>
<td></td>
</tr>
<tr>
<td>Full Body Assessment</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>No Spatial Constraints</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Exercises #</td>
<td>15</td>
<td>3</td>
<td>10 (lab version)</td>
<td>12</td>
</tr>
<tr>
<td>Compliance to MDS-UPDRS III</td>
<td>72%</td>
<td>17%</td>
<td>28%</td>
<td>56%</td>
</tr>
</tbody>
</table>
MARKET TARGET

1.4 Mln Patients in EU
118M€

650,000 Patients
Italy + Germany
55M€

122,400 Patients
11.3M€

SCALE UP

- Parkinsonisms
- Behaviour disorders
- Cognitive decline
- Clinical trials
ROADMAP, BUSINESS AND INVESTMENT MILESTONES

2014-2018
- Research projects
- Clinical prevalidation (400+ subjects tested)
- Italian patents
- Scientific publications

2020-2021
- TRL7

2022
- WE ARE HERE
- CoAlmed FOUNDATION
- Pre-Seed 200 K€
- Regulatory Plan, Manufacturing
- CE CERTIFICATION, NEW PATENT, MVP

2023
- 1st Round 1M€
- Pre-market clinical trials
- CLINICAL VALIDATION, CE IIa
- Research Market

2024
- 2nd Round 2M€
- Market scale up
- Clinical Market

2025
- SUPPORT TO DIAGNOSIS AND MONITORING
- EU Market
REVENUE MODEL

- Distributors, sellers
- Training
- Assistance
- Warranty
- Public/Private hospitals + Research centers/ universities

- Licence: 4,000€
- 8,000€

BY 5° YEAR:
Revenues = 7,300,000€
Net Income = 3,900,000€
Erika Rovini
Biomedical Engineer
PhD BioRobotics, CTO

Laura Fiorini
Biomedical Engineer
PhD BioRobotics, COO

Filippo Cavallo
Electronics Engineer
Prof. Bioengineering, Adv

Gianmaria Mancioppi
Psychologist
PhD BioRobotics, CSO

Manuele Bonaccorsi,
PhD Innovation Technology,
CEO

CLINIC ADVISORY BOARD
Dr. Carlo Maremmani
Ospedale Apuane (MS)

Dr. Silvia Ramat
Parkinson Unit AOU Careggi (FI)

Dr. Paolo Bongioanni
AOU Pisana, Cisanello (PI)

Full team: >8 experts in Computer Science, Biomedical Engineering, Product development